MARANDA DILLON: Open Payments
NPI 1376072413 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$130,137 in 303 payments from 14 companies in 2025. Trend: 2023 $5,962 · 2024 $56,509 · 2025 $130,137
Speaker / faculty: $78,539Travel & lodging: $35,899Food & beverage: $7,181Consulting: $5,769Honoraria: $2,728Education: $20
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 135 | $84,192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $17,764 |
| ABBVIE INC. | 56 | $14,329 |
| Lilly USA, LLC | 16 | $5,515 |
| Celltrion USA Inc. | 14 | $3,338 |
| Genentech USA, Inc. | 4 | $2,768 |
| Janssen Scientific Affairs, LLC | 14 | $878 |
| Merck Sharp & Dohme LLC | 7 | $729 |
| PFIZER INC. | 8 | $444 |
| Madrigal Pharmaceuticals | 3 | $72 |
Products named: TREMFYA, ENTYVIO, SKYRIZI, RINVOQ, OMVOH, ZYMFENTRA, STELARA, VELSIPITY.
Industry payments across MS — which companies pay providers there.
